GLP-1 Support Stack

A GLP-1 drug plus BPC-157/KPV for GI support (Jones's 'best overall' adds LDN — not a peptide, flagged) — GI side-effect management and keeping weight off — Jones DC masterclass; Kait on the nutrition side.

⚠ Safety first — read this before anything else on this page

Approval status: The GLP-1 layer is the only approved layer in this stack — approved in its branded pen form, for named indications. The support compounds are unapproved, and the combination has never been tested. Full page: The Vial Problem (compounded GLP-1 errors), in Dangers.

What has actually happened to people:

Compounded GLP-1 from multidose vials is the largest verified hospitalization pool in the peptide file: patients and some clinicians mis-measured and took multiples of the intended amount; some were hospitalized with severe nausea and vomiting, low blood sugar, pancreatitis, and gallstones (FDA alert, July 26, 2024). FDA counted 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.
Adding unstudied gut compounds to manage a real drug's side effects can mask the side effects that are themselves warning signs — severe GLP-1 gastrointestinal events are a reason to call the prescriber, not to add a layer.

What nobody knows: No study exists of BPC-157 or KPV alongside any GLP-1 drug. KPV has essentially no published human exposure record. Whether 'support' helps, harms, or merely hides symptoms is unknown.

Get medical care now if:

Severe or persistent vomiting, inability to keep fluids down, or severe abdominal pain on a GLP-1 — seek care promptly; these are the documented hospitalization presentations.
Signs of low blood sugar — shakiness, sweating, confusion — especially if you also take diabetes medication.
Swelling of the lips or tongue, or trouble breathing, after any injection — call emergency services.

Who should stay away: Anyone drawing GLP-1 medication from a vial without a prescriber who knows — the measurement errors in the FDA record happened to patients and clinicians alike. Anyone with a history of pancreatitis or gastroparesis should be having the GLP-1 conversation with their own doctor, not a stack page. Minors and anyone pregnant.

The product problem: FDA documents fraudulent compounded GLP-1 products bearing false labels — including labels naming pharmacies that do not exist. Of 48 GLP-1 ingredient sites FDA evaluated under Import Alert 66-80, 21% were noncompliant with manufacturing-quality requirements.

Talk to a doctor who knows you are taking it. See our doctors directory. If you were harmed, report it to FDA MedWatch — your report is how the record gets built.

We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate.

Components: A GLP-1 drug plus BPC-157/KPV for GI support (Jones’s ‘best overall’ adds LDN — not a peptide, flagged)

What creators claim: GI side-effect management and keeping weight off — Jones DC masterclass; Kait on the nutrition side.

Evidence note: The GLP-1 drug is the only approved layer; every support claim is a creator claim.

Stub page — full treatment after the transcript bank is mined for this stack. No stack on this site carries instructions of any kind.

Educational information only — not medical or legal advice. Status as of November 7, 2026. See Our Legal Mandate.

GLP-1 Support Stack

Educational information only

Before you act on anything here

THE NETWORK — ONE PUBLISHER, EVERY FRONT